AIM ImmunoTech Current Deferred Revenue (Quarterly) Insights

AIM ImmunoTech, Inc. (AIM)

1.195 -0.06 (-5.16%) USD | NYAM | Jan 23, 16:00

1.24 +0.04 (+3.77%) After-Hours: 20:00

View Current Deferred Revenue (Quarterly) for AIM.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Current Deferred Revenue (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Current Deferred Revenue (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Current Deferred Revenue (Quarterly) Benchmarks

Start Trial

Halozyme Therapeutics, Inc.	--
Perspective Therapeutics, Inc.	Upgrade
Protalix Biotherapeutics, Inc.	Upgrade
Electromed, Inc.	--
Armata Pharmaceuticals, Inc.	--